These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 32946151)

  • 1. Cardiac output improvement by pecavaptan: a novel dual-acting vasopressin V1a/V2 receptor antagonist in experimental heart failure.
    Mondritzki T; Mai TA; Vogel J; Pook E; Wasnaire P; Schmeck C; Hüser J; Dinh W; Truebel H; Kolkhof P
    Eur J Heart Fail; 2021 May; 23(5):743-750. PubMed ID: 32946151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentiation of arginine vasopressin antagonistic effects by selective V2 versus dual V2/V1a receptor blockade in a preclinical heart failure model.
    Mondritzki T; Kolkhof P; Sabbah HN; Gheorghiade M; Fürstner C; Schmeck C; Siedentop H; Schaefer S; Truebel H
    Am J Ther; 2011 Jan; 18(1):31-7. PubMed ID: 21192248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasopressin antagonism in heart failure: a review of the hemodynamic studies and major clinical trials.
    Urbach J; Goldsmith SR
    Ther Adv Cardiovasc Dis; 2021; 15():1753944720977741. PubMed ID: 33435837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands.
    Serradeil-Le Gal C; Wagnon J; Valette G; Garcia G; Pascal M; Maffrand JP; Le Fur G
    Prog Brain Res; 2002; 139():197-210. PubMed ID: 12436936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasopressin and Vasopressin Antagonists in Heart Failure.
    Vishram-Nielsen JK; Gustafsson F
    Handb Exp Pharmacol; 2017; 243():307-328. PubMed ID: 28432473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. V1a- and V2-type vasopressin receptors mediate vasopressin-induced Ca2+ responses in isolated rat supraoptic neurones.
    Gouzénes L; Sabatier N; Richard P; Moos FC; Dayanithi G
    J Physiol; 1999 Jun; 517 ( Pt 3)(Pt 3):771-9. PubMed ID: 10358117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacology of conivaptan hydrochloride (YM087), a novel vasopressin V1A/V2 receptor antagonist].
    Yatsu T; Tomura Y; Tahara A; Wada K; Kusayama T; Tsukada J; Tanaka A; Iizumi Y; Honda K
    Nihon Yakurigaku Zasshi; 1999 Oct; 114 Suppl 1():113P-117P. PubMed ID: 10629866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists.
    Perucca J; Bichet DG; Bardoux P; Bouby N; Bankir L
    J Am Soc Nephrol; 2008 Sep; 19(9):1721-31. PubMed ID: 18596120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist.
    Tahara A; Saito M; Sugimoto T; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Jan; 357(1):63-9. PubMed ID: 9459574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
    Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
    J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonpeptide antagonists for vasopressin receptors. Pharmacology of SR 121463A, a new potent and highly selective V2 receptor antagonist.
    Serradeil-Le Gal C
    Adv Exp Med Biol; 1998; 449():427-38. PubMed ID: 10026834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular Protection and Decongestion Without Renin-Angiotensin-Aldosterone System Stimulation Mediated by a Novel Dual-Acting Vasopressin V1a/V2 Receptor Antagonist.
    Kolkhof P; Pook E; Pavkovic M; Kretschmer A; Buchmüller A; Tinel H; Delbeck M; Mondritzki T; Wasnaire P; Dinh W; Truebel H; Hüser J; Schmeck C
    J Cardiovasc Pharmacol; 2019 Jul; 74(1):44-52. PubMed ID: 31274842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual Vasopressin Receptor Antagonism to Improve Congestion in Patients With Acute Heart Failure: Design of the AVANTI Trial.
    Goldsmith SR; Burkhoff D; Gustafsson F; Voors A; Zannad F; Kolkhof P; Staedtler G; Colorado P; Dinh W; Udelson JE
    J Card Fail; 2021 Feb; 27(2):233-241. PubMed ID: 33188886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
    Yamamura Y; Nakamura S; Itoh S; Hirano T; Onogawa T; Yamashita T; Yamada Y; Tsujimae K; Aoyama M; Kotosai K; Ogawa H; Yamashita H; Kondo K; Tominaga M; Tsujimoto G; Mori T
    J Pharmacol Exp Ther; 1998 Dec; 287(3):860-7. PubMed ID: 9864265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasopressin receptor antagonists in heart failure.
    Hobbs RE; Tang WH
    Recent Pat Cardiovasc Drug Discov; 2006 Jun; 1(2):177-84. PubMed ID: 18232127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of arginine vasopressin and its receptors in the normal and failing rat heart.
    Chandrashekhar Y; Prahash AJ; Sen S; Gupta S; Roy S; Anand IS
    J Mol Cell Cardiol; 2003 May; 35(5):495-504. PubMed ID: 12738231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Position three in vasopressin antagonist tolerates conformationally restricted and aromatic amino acid substitutions: a striking contrast with vasopressin agonists.
    Manning M; Cheng LL; Stoev S; Klis W; Nawrocka E; Olma A; Sawyer WH; Wo NC; Chan WY
    J Pept Sci; 1997; 3(1):31-46. PubMed ID: 9230469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure.
    Morooka H; Iwanaga Y; Tamaki Y; Takase T; Akahoshi Y; Nakano Y; Fujiki H; Miyazaki S
    Circ Heart Fail; 2012 Jul; 5(4):484-92. PubMed ID: 22628529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasopressin receptor antagonists: mechanisms of action and potential effects in heart failure.
    Goldsmith SR
    Cleve Clin J Med; 2006 Jun; 73 Suppl 2():S20-3; discussion S30-3. PubMed ID: 16786909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction between V1 and V2 effects in hemodynamic response to vasopressin in dogs.
    Liard JF
    Am J Physiol; 1990 Feb; 258(2 Pt 2):H482-9. PubMed ID: 2137987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.